COSMO Pharmaceuticals N.V.
Specialty pharma for gastroenterology/dermatology, offering colon treatments & manufacturing services.
COPN | SW
Overview
Corporate Details
- ISIN(s):
- NL0011832936
- LEI:
- 724500OX0EBQRYTVV639
- Country:
- Netherlands
- Address:
- Sir Rogerson's Quay Riverside II, Dublin 2 Dublin
- Website:
- https://www.cosmopharma.com/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
COSMO Pharmaceuticals N.V. is a specialty pharmaceutical company focused on developing and commercializing products for gastroenterology, dermatology, and healthtech. The company's therapeutic focus is on the oral and endoscopic treatment of colon diseases, including bowel diseases and colorectal cancer prevention, utilizing its proprietary MMX® technology. In addition to its own pipeline, Cosmo provides manufacturing services to other pharmaceutical companies. These services cover the production of solid, semi-solid, and liquid oral medicines and include process assessment, technology transfer, stability testing, market release, and regulatory documentation support.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-11-14 01:00 |
Regulatory News Service
Winlevi® Receives Regulatory Approval in Brazil – Expanding Global Access to a …
|
English | 5.3 KB | ||
| 2025-11-14 01:00 |
Regulatory News Service
Winlevi® erhält die behördliche Zulassung in Brasilien – Erweiterung des weltwe…
|
German | 6.3 KB | ||
| 2025-11-11 01:00 |
Environmental & Social Information
Cosmo’s ESG Rating Upgraded by S&P Global; Strengthens Supplier Sustainability …
|
English | 5.1 KB | ||
| 2025-11-11 01:00 |
Environmental & Social Information
Cosmo erhält höhere ESG-Bewertung von S&P Global, verstärkt Engagement für Nach…
|
German | 6.2 KB | ||
| 2025-11-04 01:00 |
Report Publication Announcement
Cosmo announces Upcoming Investor Events
|
English | 3.3 KB | ||
| 2025-11-04 01:00 |
Report Publication Announcement
Cosmo kündigt bevorstehende Investoren-Veranstaltungen an
|
German | 3.7 KB | ||
| 2025-11-03 01:00 |
Regulatory News Service
Cosmo Receives CE Certification for ColonPRO EU – The most Advanced AI Software…
|
English | 6.0 KB | ||
| 2025-11-03 01:00 |
Regulatory News Service
Cosmo erhält CE-Zertifizierung für ColonPRO EU – die fortschrittlichste KI-Soft…
|
German | 7.3 KB | ||
| 2025-10-21 02:00 |
Regulatory News Service
Cosmo Pharmaceuticals receives regulatory approval by the European Commission f…
|
English | 6.1 KB | ||
| 2025-10-21 02:00 |
Regulatory News Service
Cosmo Pharmaceuticals erhält nach positiver Stellungnahme des CHMP die behördli…
|
German | 7.2 KB | ||
| 2025-10-07 02:00 |
Regulatory News Service
Cosmo Pharmaceuticals announces regulatory approval of Winlevi® in South Korea
|
English | 5.2 KB | ||
| 2025-10-07 02:00 |
Regulatory News Service
Cosmo Pharmaceuticals gibt die behördliche Zulassung von Winlevi® in Südkorea b…
|
German | 6.2 KB | ||
| 2025-08-27 02:00 |
Regulatory News Service
Cosmo Receives Positive CHMP Opinion for Winlevi® for Treatment of Acne in Adul…
|
English | 7.4 KB | ||
| 2025-08-27 02:00 |
Regulatory News Service
Cosmo erhält positive CHMP-Stellungnahme für Winlevi® zur Behandlung von Akne b…
|
German | 8.8 KB | ||
| 2025-08-08 02:00 |
Regulatory News Service
Cosmo and Takeda Renew Strategic Manufacturing Agreement for Global Supply of O…
|
English | 4.7 KB |
Automate Your Workflow. Get a real-time feed of all COSMO Pharmaceuticals N.V. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for COSMO Pharmaceuticals N.V.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for COSMO Pharmaceuticals N.V. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||